NeuroPace, Inc. (NPCE)
- Previous Close
6.82 - Open
7.10 - Bid 5.19 x 200
- Ask 8.79 x 200
- Day's Range
6.83 - 7.39 - 52 Week Range
5.75 - 18.15 - Volume
34,685 - Avg. Volume
93,107 - Market Cap (intraday)
215.766M - Beta (5Y Monthly) 1.80
- PE Ratio (TTM)
-- - EPS (TTM)
-1.08 - Earnings Date Nov 4, 2024 - Nov 8, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
15.50
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
www.neuropace.comRecent News: NPCE
View MoreResearch Reports: NPCE
View MorePerformance Overview: NPCE
Trailing total returns as of 9/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NPCE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NPCE
View MoreValuation Measures
Market Cap
215.77M
Enterprise Value
233.89M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.83
Price/Book (mrq)
21.83
Enterprise Value/Revenue
3.26
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-41.63%
Return on Assets (ttm)
-15.75%
Return on Equity (ttm)
-192.19%
Revenue (ttm)
71.82M
Net Income Avi to Common (ttm)
-29.9M
Diluted EPS (ttm)
-1.08
Balance Sheet and Cash Flow
Total Cash (mrq)
55.54M
Total Debt/Equity (mrq)
745.17%
Levered Free Cash Flow (ttm)
-10.3M